XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 32.98

-0.7%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bob zagorin	5/14/2008 10:42:10 AM
	Read Replies (1) of 17367

XOMA Making the Right Moves Advancement of XOMA-052 in the current phase I trials remains the chief focus of the management of Xoma Ltd. (Nasdaq: XOMA). Data on these two trials are expected in the third quarter 2008. We expect an initiation of a phase I trial on XOMA-629 also in the third quarter 2008. Management will look to bring in one additional collaboration partner on board at some point this year. All the above milestones should get the stock moving higher in the second half of the year. We believe Xoma's antibody discovery platform is starting to show signs of paying off, as both -052 and -629 could prove to be significant products in the not-so-distant future. The name remains significantly under-valued in our view. Royalty revenue continues to provide meaningful growth to Xoma. Sales of Raptiva totaled $61 million in the first quarter 2008. Sales of Lucentis totaled $393 million in the first quarter. Both products are growing at double-digits rates. In May 2008 Xoma used this growing royalty line to secure a $55 million loan with Goldman Sachs (NYSE: GS). But with the shares trading at $2.15, Xoma is a very volatile stock.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next